Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management

被引:239
作者
Rampton, David [1 ]
Folkersen, Joergen [2 ]
Fishbane, Steven [3 ]
Hedenus, Michael [4 ]
Howaldt, Stefanie [5 ]
Locatelli, Francesco [6 ]
Patni, Shalini [7 ]
Szebeni, Janos [8 ]
Weiss, Guenter [9 ]
机构
[1] Barts & London Queen Marys Sch Med & Dent, London, England
[2] Medbusiness, Farum, Denmark
[3] Hofstra North Shore LIJ Sch Med, New York, NY USA
[4] Sundsvalls Hosp, Dept Haematol, Sundsvall, Sweden
[5] HaFCED GmbH&Co KG, Res Inst IBD, Hamburg, Germany
[6] Alessandro Manzoni Hosp, Lecce, Italy
[7] Birmingham Heartlands Hosp, Birmingham, W Midlands, England
[8] Semmelweis Univ, Nanomed Res & Educ Ctr, H-1085 Budapest, Hungary
[9] Med Univ Innsbruck, Dept Internal Med 6, A-6020 Innsbruck, Austria
关键词
ANAPHYLACTOID REACTIONS; DEXTRAN; GUIDELINES; SEVERITY; PRODUCTS; SAFETY; UPDATE; ANEMIA;
D O I
10.3324/haematol.2014.111492
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intravenous iron is widely used for the treatment of iron deficiency anemia when oral iron is inappropriate, ineffective or poorly tolerated. Acute hypersensitivity reactions during iron infusions are very rare but can be life-threatening. This paper reviews their frequency, pathogenesis and risk factors, and provides recommendations about their management and prevention. Complement activation-related pseudo-allergy triggered by iron nanoparticles is probably a more frequent pathogenetic mechanism in acute reactions to current formulations of intravenous iron than is an immunological IgE-mediated response. Major risk factors for hypersensitivity reactions include a previous reaction to an iron infusion, a fast iron infusion rate, multiple drug allergies, severe atopy, and possibly systemic inflammatory diseases. Early pregnancy is a contraindication to iron infusions, while old age and serious co-morbidity may worsen the impact of acute reactions if they occur. Management of iron infusions requires meticulous observation, and, in the event of an adverse reaction, prompt recognition and severity-related interventions by well-trained medical and nursing staff.
引用
收藏
页码:1671 / 1676
页数:6
相关论文
共 31 条
[1]   Clinical update: intravenous iron for anaemia [J].
Auerbach, Michael ;
Ballard, Harold ;
Glaspy, John .
LANCET, 2007, 369 (9572) :1502-1504
[2]   Clinical Use of Intravenous Iron: Administration, Efficacy, and Safety [J].
Auerbach, Michael ;
Ballard, Harold .
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2010, :338-347
[3]  
Bailie George R, 2012, Clin Adv Hematol Oncol, V10, P101
[4]   Comparison of rates of reported adverse events associated with i.v. iron products in the United States [J].
Bailie, George R. .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (04) :310-320
[5]   EFFECT OF INTRAVENOUS IRON DEXTRAN ON RHEUMATOID SYNOVITIS [J].
BLAKE, DR ;
LUNEC, J ;
AHERN, M ;
RING, EFJ ;
BRADFIELD, J ;
GUTTERIDGE, JMC .
ANNALS OF THE RHEUMATIC DISEASES, 1985, 44 (03) :183-188
[6]   Clinical features and severity grading of anaphylaxis [J].
Brown, SGA .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 114 (02) :371-376
[7]   On the relative safety of intravenous iron formulations: New answers, new questions [J].
Chertow, Glenn M. ;
Winkelmayer, Wolfgang C. .
AMERICAN JOURNAL OF HEMATOLOGY, 2010, 85 (09) :643-644
[8]   Update on adverse drug events associated with parenteral iron [J].
Chertow, GM ;
Mason, PD ;
Vaage-Nilsen, O ;
Ahlmén, J .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (02) :378-382
[9]  
Critchley J., 2007, Transfusion Alternatives in Transfusion Medicine, V9, P8, DOI [DOI 10.1111/J.1778-428X.2007.00042.X, 10.1111/j.1778-428X.2007.00042.x]
[10]   Explaining risks: turning numerical data into meaningful pictures [J].
Edwards, A ;
Elwyn, G ;
Mulley, A .
BMJ-BRITISH MEDICAL JOURNAL, 2002, 324 (7341) :827-830